 RespireRx Pharmaceuticals OTCQB:RSPI Inc revealed that scientists associated with the company have published a paper about its candidate KRM-II-81, which is a so-called GABAkine - a type of medicine which enhances the inhibitory neurotransmitter in the brain. RespireRx is advancing a portfolio of innovative drugs to combat neurological and psychiatric conditions and its EndeavourRx business unit is advancing KRM-II-81 to treat epilespy and chronic pain. 